Cargando…
G2/M-Phase-Inhibitory Mitochondrial-Depolarizing Re(I)/Ru(II)/Ir(III)-2,2′-Bipyrimidine-Based Heterobimetallic Luminescent Complexes: An Assessment of In Vitro Antiproliferative Activity and Bioimaging for Targeted Therapy toward Human TNBC Cells
[Image: see text] Triple-negative breast cancer (TNBC) is an extremely vicious subtype of human breast cancer having the worst prognosis along with strong invasive and metastatic competency. Hence, it can easily invade into blood vessels, and presently, no targeted therapeutic approach is available...
Autores principales: | Roy, Nilmadhab, Shanavas, Shanooja, Kar, Binoy, Thilak Babu, Lavanya, Das, Utpal, Vardhan, Seshu, Sahoo, Suban K., Bose, Bipasha, Rajagopalan, Vijayaraghavan, Paira, Priyankar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077533/ https://www.ncbi.nlm.nih.gov/pubmed/37033791 http://dx.doi.org/10.1021/acsomega.2c08285 |
Ejemplares similares
-
Mitochondria-targeted half-sandwich iridium(iii)-Cp*-arylimidazophenanthroline complexes as antiproliferative and bioimaging agents against triple negative breast cancer cells MDA-MB-468
por: Mondal, Ashaparna, et al.
Publicado: (2022) -
Ru(ii)arene(N^N bpy/phen)-based RAPTA complexes for in vitro anti-tumour activity in human glioblastoma cancer cell lines and in vivo toxicity studies in a zebrafish model
por: P. K., Anuja, et al.
Publicado: (2022) -
CuAAC “Click”-Derived
Luminescent 2-(2-(4-(4-(Pyridin-2-yl)-1H-1,2,3-triazol-1-yl)butoxy)phenyl)benzo[d]thiazole-Based Ru(II)/Ir(III)/Re(I) Complexes as Anticancer
Agents
por: Thilak Babu, Lavanya, et al.
Publicado: (2023) -
Different routes for the construction of biologically active diversely functionalized bicyclo[3.3.1]nonanes: an exploration of new perspectives for anticancer chemotherapeutics
por: Roy, Nilmadhab, et al.
Publicado: (2023) -
Computational studies on the interaction of SARS-CoV-2 Omicron SGp RBD with human receptor ACE2, limonin and glycyrrhizic acid
por: Vardhan, Seshu, et al.
Publicado: (2022)